跳至主要内容
临床试验/ISRCTN68399350
ISRCTN68399350已完成2 期

A randomised trial for the Treatment of cardiac AMyloid light-chain amyloidosis with the green tea compound Epigallocatechin-3-gALlate (TAME-AL)

Ruprecht-Karls-University of Heidelberg (Germany)0 个研究点目标入组 38 人开始时间: 2012年10月5日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
38

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Biopsy proven systemic AL amyloidosis
  • 2. Cardiac involvement with septum thickness >12 mm (without other causes as published by Gertz et al)
  • 3. Hypertension or other potential causes of left ventricular hypertrophy
  • 4. Previously treated with chemotherapy
  • 5. Induced at least a very good partial remission of the underlying monoclonal plasma cell or B cell disorder

排除标准

  • 1. Age < 18 years
  • 2. Concomitant multiple myeloma stage II and III (Salmon and Durie)
  • 3. Concurrent chemotherapy necessary
  • 4. Time to last chemotherapy > 6 months
  • 5. Chronic liver disease
  • 6. Bilirubin > 1,5 mg/dl
  • 7. Not able to visit Amyloidosis Clinic in Heidelberg every 3 months

研究者

发起方
Ruprecht-Karls-University of Heidelberg (Germany)

相似试验

Treatment of cardiac amyloid light-chain amyloidosis... | 临床试验